COVID-19. TO DEVELOP AND PROGRESS HDT-301, A REPLICON RNA ENCODING SARS-COV-2 SPIKE PROTEIN BOUND TO LIPID INORGANIC NANOPARTICLE (LION) FORMULATION TO PROTECT AGAINST COVID-19, THROUGH A PHASE I CLINICAL TRIAL.

DEFINITIVE CONTRACT won by HDT BIO CORP · work in SEATTLE, WA
$10,970,058
RecipientHDT BIO CORP UEI Z33DCMWXZBK7
Award ID75N93020C00052
Award amount$10,970,058
Award typeDEFINITIVE CONTRACT
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSCAJ12
Start dateSep 1, 2020
End dateOct 31, 2023
Place of performanceSEATTLE, WA
Record updatedSep 1, 2022

View the official award record

More awards won by HDT BIO CORP

ADAPTABLE RNA-BASED ANTIBODY PLATFORM FOR PROTECTION AGAINST CONTEMPORARY/EMERGING HUMAN ENTEROVIRUSES
Department of Health and Human Services · $1,499,422 · Jul 1, 2022
HDT BIO CORP - AOI #21 VACCINE ON DEMAND: R&D USE OF LION-REPRNA IN RAPID RESPONSE VACCINE DEVELOPMENT
Department of Health and Human Services · $749,000 · Sep 22, 2023
RATIONAL DEVELOPMENT OF A COMBINATION NANOPARTICLE ADJUVANT FOR INFLUENZA.
Department of Health and Human Services · $599,629 · Sep 1, 2019

Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.

Search open bids